Tetrapyrrole Radionuclide Compound Enzymatic Self-Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating diseases, particularly cancer, lack effective compounds that can selectively target and immobilize radionuclides at specific sites within the body, such as tumors, due to limitations in molecular design and enzymatic action under physiological conditions.
Innovation Solution
A compound comprising a tetrapyrrole macrocycle with a radionuclide, a hydrogelator, a water solubilizing group, and a cleavage site between the hydrogelator and the water solubilizing group, which self-assembles upon enzymatic action, allowing for targeted radionuclide immobilization and aggregation, particularly at tumor sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a radionuclide compound is administered systemically, then it can reach target sites throughout the body, but it diffuses non-selectively and cannot be immobilized at specific locations
Solution Approach 1:
The compound is divided into distinct functional segments: a radionuclide-bearing tetrapyrrole macrocycle, a hydrogelator component, a water solubilizing group, and an enzyme-sensitive cleavage site. This segmentation allows the molecule to circulate systemically in a soluble state and then self-assemble at target sites through enzymatic triggering, achieving both systemic distribution and localized precision.
Solution Approach 2:
The compound is pre-designed with all necessary components (radionuclide, hydrogelator, solubilizing group, cleavage site) incorporated into a single molecular structure that remains stable during systemic circulation. The preliminary configuration enables the molecule to reach target tissues before enzymatic activation triggers self-assembly and immobilization.
2Reliability
If compounds are designed for enzymatic action under physiological conditions, then selective targeting is achieved, but new compounds and methods are needed due to limitations in current molecular design
Solution Approach 1:
The compound autonomously performs multiple functions: it self-solubilizes in physiological conditions, self-targets to enzyme-rich regions, self-assembles into aggregates upon enzymatic cleavage, and self-immobilizes the radionuclide at the target site. This self-service capability reduces the need for complex external control mechanisms while achieving reliable selective targeting.
Solution Approach 2:
The invention integrates multiple functional components into a single composite molecular structure: the tetrapyrrole macrocycle provides radionuclide coordination, the hydrogelator enables self-assembly, the water solubilizing group ensures bioavailability, and the cleavage site provides enzymatic responsiveness. This composite design achieves selective targeting while managing molecular complexity through functional integration.
3Measurement precision
If radionuclides are immobilized at target sites, then diagnostic and therapeutic efficacy is enhanced, but systemic diffusion must be minimized
Solution Approach 1:
The compound undergoes a phase transition from a soluble monomeric state during systemic circulation to an insoluble aggregated hydrogel state at the target site. This phase transition is triggered by enzymatic cleavage of the solubilizing group, causing the hydrogelator to self-assemble and immobilize the radionuclide, thereby preventing systemic diffusion while enhancing local efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise diagnosis and treatment by aggregating and immobilizing radionuclides at desired locations within the body, such as tumors, through enzymatically triggered self-assembly, enhancing diagnostic and therapeutic efficacy while minimizing systemic diffusion.
Implementation Method 1
a cleavage site that is between the hydrogelator and the water solubilizing group... a cleavage agent (e.g., an enzyme) present in the subject cleaves the compound at the cleavage site
Implementation Method 2
two or more compounds of the present invention self-assemble (e.g., aggregate) in the subject... the resulting scaffold can be exploited to achieve immobilization at desired sites
Data Source
AI summary
Compounds comprising a tetrapyrrole macrocycle that includes a radionuclide; a hydrogelator attached to the tetrapyrrole macrocycle; a water solubilizing group attached to the hydrogelator; and a cleavage site that is between the hydrogelator and the water solubilizing group are described herein along with their methods of use. Two or more compounds of the present invention may two or more compounds may self-assemble (e.g., aggregate), optionally in vivo.